McKay Tina B, Karamichos Dimitrios
1 Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104,USA.
2 Department of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, OK 73104, USA.
Exp Biol Med (Maywood). 2017 Mar;242(6):565-572. doi: 10.1177/1535370216685187. Epub 2017 Jan 5.
Flavonoids are a class of plant and fungus secondary metabolites that serve functional roles in protecting against UV-induced oxidative stress, mediating auxin signaling, and promoting microbial defense. Flavonoids are extremely abundant in nature where their potent antioxidant capacity and very low toxicity makes them highly attractive as potential therapeutic agents. In terms of clinical applications, neither the Food and Drug Administration (FDA) nor the European Food Safety Authority (EFSA) has approved any health claims or drugs related to the use of flavonoids for therapeutic purposes. Quercetin is a common flavonol that has been shown to have potent antioxidant, anti-inflammatory, and anti-fibrotic activities both in vitro and in vivo in various tissues. Recently, the application of quercetin as a therapeutic has been gaining attention in the ocular surface scientific community in the study of dry eye, keratoconus, inflammation, and neovascularization of the cornea. This review will discuss the latest findings and the use of quercetin for the treatment of dystrophies of the ocular surface. Impact statement The eye represents a small portion of the human body, accounting for one decimal fraction of the anterior body surface. The cornea is an avascular, transparent tissue that acts as a primary barrier against mechanical and infectious damaging agents, protecting the internal structures of the eye. Corneal survival and function are affected by a number of factors including but not limited to injury, trauma, infection, genetics, and environment. Corneal injury, or trauma, often leads to loss of corneal transparency and even blindness. The concept of "curing" corneal opacity has been discussed in published form for over 200 years. Currently, full corneal transplant is the only treatment option. There is a strong interest in developing natural therapeutic products that come with minimum side effects. A novel antioxidant flavonoid, quercetin, has been gaining traction as a potential therapeutic to prevent the injured cornea. This review discusses the potential of this antioxidant.
黄酮类化合物是一类植物和真菌的次生代谢产物,在抵御紫外线诱导的氧化应激、介导生长素信号传导以及促进微生物防御方面发挥着功能性作用。黄酮类化合物在自然界中极为丰富,其强大的抗氧化能力和极低的毒性使其作为潜在治疗剂极具吸引力。在临床应用方面,美国食品药品监督管理局(FDA)和欧洲食品安全局(EFSA)均未批准任何与将黄酮类化合物用于治疗目的相关的健康声明或药物。槲皮素是一种常见的黄酮醇,已被证明在体外和体内的各种组织中均具有强大的抗氧化、抗炎和抗纤维化活性。最近,在干眼、圆锥角膜、炎症和角膜新生血管形成的研究中,槲皮素作为一种治疗药物在眼表科学界受到了越来越多的关注。本综述将讨论槲皮素治疗眼表营养不良的最新研究结果及应用。影响声明眼睛仅占人体的一小部分,占身体前表面的千分之一。角膜是一种无血管的透明组织,作为抵御机械性和感染性损伤因子的主要屏障,保护眼睛的内部结构。角膜的存活和功能受到多种因素的影响,包括但不限于损伤、创伤、感染、遗传和环境。角膜损伤或创伤通常会导致角膜透明度丧失甚至失明。“治愈”角膜混浊的概念已以公开形式讨论了200多年。目前,全角膜移植是唯一的治疗选择。人们对开发副作用最小的天然治疗产品有着浓厚的兴趣。一种新型抗氧化黄酮类化合物槲皮素作为预防角膜损伤的潜在治疗药物正受到越来越多的关注。本综述讨论这种抗氧化剂的潜力。